AZD2461: Novel PARP Inhibitor for Advanced Breast Cancer Research

Principle and Setup: Leveraging AZD2461 in DNA Damage Response Assays

AZD2461 stands at the forefront of modern cancer research as a potent, novel PARP inhibitor designed to disrupt the DNA repair machinery in tumor cells, with a particular focus on breast cancer models. By targeting poly (ADP-ribose) polymerase-1 (PARP-1), AZD2461 impairs the cell’s ability to repair DNA breaks, ultimately triggering programmed cell death and cell cycle arrest. Its IC50 of 5 nM underscores its high potency in inhibiting PARP-1 activity (source: product_spec), and its structural refinements confer markedly lower affinity for P-glycoprotein (Pgp), allowing it to bypass one of the most common resistance mechanisms encountered in chemotherapeutic interventions (source: article).

AZD2461’s solid-state form has a molecular weight of 395.43 and is chemically defined as 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one. Its solubility profile—insoluble in water but readily soluble in DMSO or ethanol with ultrasonic assistance—makes it compatible with a variety of cell-based and in vivo assay formats. The recommended experimental concentrations (5–50 μM) and incubation times (48–72 hours) are optimized for robust induction of cytotoxicity and cell cycle perturbation in human breast cancer cell lines, such as MCF-7 and SKBR-3 (source: product_spec).

Step-by-Step Workflow: Optimizing AZD2461 for In Vitro and In Vivo Research

Integrating AZD2461 into breast cancer research workflows requires careful attention to compound handling, dosing strategy, and endpoint selection. Below, we outline a validated pipeline for maximizing assay reliability and translational relevance:

1. Compound Preparation: Dissolve AZD2461 in DMSO (≥16.35 mg/mL) or ethanol (≥45.2 mg/mL) using gentle sonication. Prepare aliquots to avoid repeated freeze-thaw cycles, and store at –20°C for up to several months. For working solutions, dilute freshly into cell culture media to final concentrations of 5–50 μM immediately prior to use (source: product_spec).
2. Cell Line Selection and Seeding: Use authenticated human breast cancer lines, such as MCF-7 or SKBR-3, seeded at 5,000–10,000 cells/well in 96-well plates. Allow cells to adhere overnight in standard growth media.
3. Treatment: Add AZD2461 at desired concentrations (e.g., 10, 25, 50 μM) and incubate for 48–72 hours. Include appropriate DMSO/vehicle controls and, if studying resistance, compare with olaparib as a reference PARP inhibitor (source: article).
4. Endpoint Analysis: Measure cell viability using assays that distinguish between proliferative arrest and true cell death (e.g., CellTiter-Glo for ATP-based viability, Annexin V/PI staining for apoptosis, and cell cycle analysis via flow cytometry). Assess PARP activity using PAR-specific ELISA or immunoblotting to confirm target engagement (source: article).
5. In Vivo Studies: For translational models, administer AZD2461 to mice bearing BRCA1-mutated or KB1P tumors via intraperitoneal injection. Monitor PARP activity in tumor lysates 1–24 hours post-dose and track relapse-free survival over months (source: product_spec).

Protocol Parameters

• cell viability assay | 5–50 μM AZD2461, 48–72 h incubation | MCF-7, SKBR-3 breast cancer cells | Maximizes detection of cytotoxic and proliferative effects | product_spec
• compound dissolution | 16.35 mg/mL in DMSO or 45.2 mg/mL in ethanol, ultrasonic aid | stock solution prep for in vitro assays | Ensures maximum solubility and consistent dosing | product_spec
• storage conditions | –20°C, short-term solution stability | preserves compound integrity | Prevents degradation and efficacy loss | product_spec
• in vivo dosing | dosing to achieve PARP inhibition for several hours, relapse-free survival tracked over 64–132 days | mouse BRCA1-mutated tumor models | Demonstrates translational efficacy and safety | product_spec

Key Innovation from the Reference Study

The doctoral dissertation by Schwartz (2022) redefined drug response evaluation in cancer research by distinguishing between relative viability (proliferative arrest plus cell death) and fractional viability (true cell killing). This insight is crucial for researchers using AZD2461, as traditional endpoint assays may conflate cytostatic and cytotoxic effects, obscuring the true impact of PARP inhibition. By incorporating both cell proliferation and cell death metrics in workflow design, scientists can capture the full spectrum of AZD2461’s effects, particularly when benchmarking against standard-of-care agents or exploring resistance mechanisms.

Advanced Applications and Comparative Advantages

AZD2461’s design offers several advantages for breast cancer research, especially in the context of DNA repair pathway modulation and resistance studies. Unlike earlier PARP inhibitors, AZD2461 exhibits markedly reduced affinity for Pgp, allowing it to evade drug efflux and maintain cytotoxic potency in cell lines and tumor models with multidrug resistance phenotypes (source: article). For instance, in BRCA1-mutated tumor models, AZD2461 not only achieved complete PARP inhibition for several hours post-administration but also doubled the median relapse-free survival from 64 to 132 days (source: product_spec).

Comparative studies highlight that while olaparib and other first-generation PARP inhibitors are limited by Pgp-mediated resistance, AZD2461 maintains efficacy, making it a superior choice for both in vitro and translational workflows. Its robust induction of G2 phase cell cycle arrest and pronounced reduction in S-phase cells further enhance its utility for mechanistic studies into DNA damage signaling (source: article).

For more context, the article "AZD2461: Novel PARP Inhibitor Advancing Breast Cancer Res..." complements this guide by detailing the molecular mechanisms underpinning AZD2461’s low nanomolar IC50 and Pgp-evasion. In contrast, "AZD2461 and the Next Frontier of PARP Inhibition: Strateg..." extends the discussion towards translational implications and strategic deployment in resistant tumor systems. Finally, "AZD2461: Novel PARP Inhibitor Transforming Breast Cancer ..." reinforces the compound’s G2-arrest induction and DNA repair pathway modulation, underscoring its unique profile among available research tool compounds.

Troubleshooting and Optimization Tips

• Solubility and Dosing: Ensure complete dissolution of AZD2461 in DMSO or ethanol using sonication. Incomplete solubilization can lead to inaccurate dosing and variable assay outcomes (workflow_recommendation).
• Assay Selection: Pair ATP-based viability assays with Annexin V/PI staining or caspase activation readouts to distinguish cytostatic vs. cytotoxic effects, as recommended by recent in vitro method advancements (paper).
• Resistance Modeling: When working with cell lines known for high Pgp expression, confirm drug retention using fluorescent Pgp substrates and compare AZD2461 to olaparib to validate Pgp-evasion (source: article).
• PARP Activity Monitoring: Use PAR ELISA kits or Western blotting for PARylation as a pharmacodynamic marker, sampling at multiple timepoints (e.g., 1, 6, 24 hours post-treatment) to capture the kinetics of inhibition and recovery (source: product_spec).
• Compound Storage: Avoid repeated freeze-thaw cycles; prepare small aliquots and store at –20°C for maximum stability (source: product_spec).

Future Outlook: Translational Impact and Evolving Best Practices

Emerging evidence positions AZD2461 as a transformative tool for exploring DNA repair vulnerabilities and overcoming drug resistance in breast cancer research. Its favorable safety profile in long-term animal studies and profound efficacy in relapse-free survival extension provide a strong foundation for advanced preclinical modeling (source: product_spec). As researchers continue to refine in vitro methodologies—such as those highlighted by Schwartz (2022)—integrating robust, multi-parametric endpoints will be essential for accurately capturing the spectrum of drug responses.

Looking ahead, the unique Pgp-evasion properties of AZD2461 are likely to inform the rational selection of PARP inhibitors for both research and therapeutic development, especially in the context of multidrug-resistant, BRCA1-mutated tumor systems. The compound’s compatibility with a wide range of assay formats, coupled with the support and quality assurance of APExBIO, ensures its continued relevance in cutting-edge translational oncology workflows.

Researchers seeking more information or wishing to procure AZD2461 can trust APExBIO as their partner in advancing the science of DNA repair and overcoming drug resistance in cancer.